DRTX Stock UPDATES Durata Therapeutics Inc (DRTX) 14.15 08/10/2014

New Post Public Reply Private Reply Replies (0) Message Board

Aug 10, 2014 at 8:22 PM

Durata Therapeutics Inc (DRTX) 14.15 $DRTX

3 Biotech Stocks to End Q2 on a Winning Note - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 2:54PM CDT
The rebound was due to strong earnings reports, product approvals, and acquisitions and licensing deals.

Nasdaq stocks posting largest percentage decreases
AP - Thu Aug 07, 5:14PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:

Durata Therapeutics Reports Second Quarter 2014 Financial Results
GlobeNewswire - Thu Aug 07, 6:08AM CDT
Durata Therapeutics, Inc. (Nasdaq

RTX) today announced financial results for the quarter ended June 30, 2014.

Durata Therapeutics to Present at Upcoming Investor Conference
GlobeNewswire - Wed Aug 06, 7:30AM CDT
Durata Therapeutics (Nasdaq

RTX) announced today that Paul R. Edick, Chief Executive Officer, will present at the Wedbush 2014 Life Sciences Management Access Conference on August 13, 2014 at 9:45am EDT in New York, New York.

Durata Therapeutics (DRTX) Worth Watching: Stock Gains 18.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 8:46AM CDT
Durata Therapeutics (DRTX) was a big mover last session, with shares rising nearly 19% on the day.

The Zacks Analyst Blog Highlights: AbbVie, Shire, ARIAD Pharmaceuticals, ImmunoGen and Durata Therapeutics
PR Newswire - Fri Aug 01, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the AbbVie Inc. (NYSE:ABBV-Free Report), Shire (Nasdaq:SHPG-Free Report), ARIAD Pharmaceuticals, Inc. (Nasdaq:ARIA-Free Report), ImmunoGen, Inc. (Nasdaq:IMGN-Free Report) and Durata Therapeutics, Inc. (Nasdaq

RTX-Free Report).

3 Eye-Catching Health Care Stocks this Earnings Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 10:44AM CDT
These stocks are well positioned in today’s market environment.

Durata Therapeutics to Report Second Quarter 2014 Financial Results on August 7, 2014
GlobeNewswire - Thu Jul 31, 7:30AM CDT
Durata Therapeutics, Inc. (Nasdaq

RTX) has scheduled its quarterly conference call for Thursday, August 7 at 8:30 a.m. Eastern Time to discuss second quarter 2014 financial results.

Durata Therapeutics Enters Into an Exclusive License and Supply Agreement With Angelini to Commercialize Dalbavancin in Certain European Territories, Russia and Turkey
GlobeNewswire - Wed Jul 30, 7:40AM CDT
Durata Therapeutics, Inc. (Nasdaq

RTX) announced today that its Dutch subsidiary, Durata Therapeutics International B.V., has entered into a license and supply agreement with Angelini, an international group leader in the pharmaceutical and mass-market sectors, to commercialize dalbavancin in 36 countries, which include Italy, Spain, Poland, Portugal, many Eastern European countries, Russia, Turkey, and Commonwealth of Independent States.

United Therapeutics (UTHR) Jumps: Stock Adds 8.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 7:37AM CDT
United Therapeutics Corporation (UTHR) was a big mover last session, as the company saw its shares rise more than 8% on the day

Durata Therapeutics unveils DALVANCE for injection for treating acute bacterial skin and skin structure infections
M2 - Mon Jul 21, 6:59AM CDT
Pharmaceutical company Durata Therapeutics (NasdaqGM

RTX) disclosed on Monday the market availability of DALVANCE (dalbavancin) for injection for treating adult patients with acute bacterial skin and skin structure infections (ABSSSI).

Investing to Fight Toilet and Elevator Superbugs
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Sat Jul 19, 2:00PM CDT
A big thank-you to our friends at FierceHealthcare for an incredible story about how a recent study indicated that hospital elevator buttons might have a higher prevalence of bacteria colonization than toilets. Yes, you read that correctly....

Durata Therapeutics Announces the U.S. Launch of DALVANCE(TM)
GlobeNewswire - Fri Jul 18, 6:59AM CDT
Durata Therapeutics, Inc. (Nasdaq

RTX) announced today that DALVANCE (dalbavancin) for injection is now available for use to treat adult patients with acute bacterial skin and skin structure infections (ABSSSI). DALVANCE was approved by the U.S. Food and Drug Administration (FDA) on May 23, 2014 and was the first drug approved as a Qualified Infectious Disease Product (QIDP). Durata began shipping DALVANCE to its distributors earlier this week. Physicians and Pharmacists may now order DALVANCE from ASD Healthcare or their wholesaler, or they may call Durata at 1 855 DURATA1 (1-855-387-2821).

Cubist and Durata Heat Up Antibiotic Market
Brian Orelli, The Motley Fool - Motley Fool - Mon Jun 23, 4:30PM CDT
Antibiotics are on a comeback. And Cubist Pharmaceuticals is in the middle of it. Gone are the days when it seemed the Food and Drug Administration had a bone to pick with every antibiotic drugmaker. On Friday, the agency approved its second...

Cubist Gains FDA Approval for Sivextro - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 10:50AM CDT
Cubist's (CBST) Sivextro gained FDA approval for the ABSSSI indication.

FDA approves Cubist antibiotic for skin infections
By MATTHEW PERRONE - AP - Fri Jun 20, 5:32PM CDT
WASHINGTON (AP) — The Food and Drug Administration on Friday approved a new antibiotic from Cubist Pharmaceuticals to treat common skin infections often acquired in the hospital.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

WHO and RCSI Bahrain Join Forces on Health Initiatives

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

PASCAL's Holiday Gift Edit: Timeless Watches Shine

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Fluence Energy Faces Leadership Departures Amid Legal Woes

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Webull Faces Class Action: Key Details for Investors

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Retirement Dreams Dashed: 61% Withdraw Early

By Olivia Taylor Updated Nov 14, 2026 Category News Views 382

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Luvme Hair Offers Wig Variety for Winter Fashion

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

El Pollo Loco Faces Class Action Over Wage Practices

Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...